SRI 31215 TFA |
Catalog No.GC34811 |
SRI 31215 (TFA) es un inhibidor triplex matriptasa/hepsina/activador del factor de crecimiento de hepatocitos (HGFA) e imita la actividad de HAI-1/2 (inhibidores endÓgenos de la activaciÓn de HGF). SRI 31215 tiene una potente actividad inhibidora contra matriptasa, hepsina y HGFA con valores de IC50 de 0,69 μM, 0,65 μM y 0,30 μM, respectivamente. SRI 31215 se puede utilizar para la investigaciÓn del cÁncer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1832686-44-8
Sample solution is provided at 25 µL, 10mM.
SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2[1]. IC50: 0.69 μM (matriptase), 0.65 μM (hepsin), 0.3 μM (HGFA)[1]
[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *